JPH081438B2 - Enzyme immunoassay - Google Patents

Enzyme immunoassay

Info

Publication number
JPH081438B2
JPH081438B2 JP62083656A JP8365687A JPH081438B2 JP H081438 B2 JPH081438 B2 JP H081438B2 JP 62083656 A JP62083656 A JP 62083656A JP 8365687 A JP8365687 A JP 8365687A JP H081438 B2 JPH081438 B2 JP H081438B2
Authority
JP
Japan
Prior art keywords
antibody
cea
tsh
peroxidase
beads
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP62083656A
Other languages
Japanese (ja)
Other versions
JPS63118656A (en
Inventor
泰彦 田中
正和 杉浦
一登 坂田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanyo Chemical Industries Ltd
Original Assignee
Sanyo Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanyo Chemical Industries Ltd filed Critical Sanyo Chemical Industries Ltd
Publication of JPS63118656A publication Critical patent/JPS63118656A/en
Publication of JPH081438B2 publication Critical patent/JPH081438B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306Solid-phase reaction mechanisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/552Glass or silica
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Description

【発明の詳細な説明】 [産業上の利用分野] 本発明は、酵素免疫測定法に関する。TECHNICAL FIELD The present invention relates to an enzyme immunoassay method.

[従来の技術] 従来、酵素免疫測定法として、不溶性固体上の第一抗
体に結合した抗原性物質に酵素を標識した第二抗体を反
応させ、その酵素量を測定する方法(いわゆる、サンド
イッチ法)がある[たとえば、石川栄治、河合忠、宮井
潔編、「酵素免疫測定法」医学書院P45(1982)]。
[Prior Art] Conventionally, as an enzyme immunoassay, a method in which an antigenic substance bound to a first antibody on an insoluble solid is reacted with a second antibody labeled with an enzyme and the amount of the enzyme is measured (a so-called sandwich method) ) [For example, Eiji Ishikawa, Tadashi Kawai, Kiyoshi Miyai, "Enzyme-linked immunosorbent assay", Medical Institute P45 (1982)].

[発明が解決しようとする問題点] しかし、この技術では、第二抗体の抗体価が低い場
合、十分な測定感度が得られない。
[Problems to be Solved by the Invention] However, with this technique, when the antibody titer of the second antibody is low, sufficient measurement sensitivity cannot be obtained.

[問題を解決するための手段] 本発明者らは、抗体価の弱い第二抗体を使用した場合
においても、十分な測定感度が得られる酵素免疫測定法
につき、鋭意検討した結果、本発明に到達した。
[Means for Solving the Problem] The present inventors have conducted extensive studies on enzyme immunoassays that provide sufficient measurement sensitivity even when a second antibody having a low antibody titer is used, and as a result, the present invention Arrived

すなわち本発明は、 癌胎児性抗原(CEA)および甲状腺刺激ホルモン(TSH)
から選ばれる抗原性物質を認識する不溶性固体上の抗体
(第一抗体)、前記CEAおよびTSHから選ばれる抗原性物
質、および前記第一抗体とは異なる動物種由来の前記抗
原性物質を認識する抗体(第二抗体)を同時に反応させ
て得た免疫複合体と、 ペルオキシダーゼで標識された、前記第一抗体と同じ動
物種由来の抗体であり、第二抗体と同じ動物種由来の免
疫グロブリンを認識するペルオキシダーゼ標識抗体(第
三抗体) とを反応させたのち、ペルオキシダーゼ標識抗体と反応
させたのち、酵素量を測定することにより、前記抗原性
物質を定量することを特徴とする酵素免疫測定法であ
る。
That is, the present invention relates to carcinoembryonic antigen (CEA) and thyroid stimulating hormone (TSH).
An antibody on an insoluble solid that recognizes an antigenic substance selected from (first antibody), an antigenic substance selected from the CEA and TSH, and the antigenic substance derived from an animal species different from the first antibody An immune complex obtained by reacting an antibody (second antibody) at the same time and an immunoglobulin derived from the same animal species as the first antibody, which is labeled with peroxidase, are derived from the same animal species as the second antibody. An enzyme immunoassay method characterized in that the antigenic substance is quantified by reacting with a peroxidase-labeled antibody (third antibody) that recognizes, then reacting with the peroxidase-labeled antibody, and then measuring the enzyme amount. Is.

本発明は、癌胎児性抗原(CEA)および甲状腺刺激ホ
ルモン(TSH)から選ばれる抗原性物質を測定対象とす
る方法である。CEAおよびTSHは特に高感度の測定系が要
求される抗原性物質である。
The present invention is a method for measuring an antigenic substance selected from carcinoembryonic antigen (CEA) and thyroid stimulating hormone (TSH). CEA and TSH are antigenic substances that require particularly sensitive measurement systems.

不溶性固体としては、ケイ酸質無機担体[ガラス(ポ
ーラスガラス,ツヤ消しガラスなど),シリカゲル,ベ
ントナイトなど]、磁性体、および有機担体(プラスチ
ック,デキストラン,口紙など)があげられる。これら
のうち、好ましくは、簡便かつ安定して抗体が結合で
き、さらに、取扱いが容易なガラス(ガラスビーズおよ
びガラス試験管),およびプラスチック(プラスチック
チューブおよびプラスチックトレイ)である。
Examples of the insoluble solid include siliceous inorganic carriers [glass (porous glass, matte glass, etc.), silica gel, bentonite, etc.], magnetic materials, and organic carriers (plastic, dextran, mouth paper, etc.). Of these, preferred are glass (glass beads and glass test tubes) and plastic (plastic tubes and plastic trays), which are simple and stable to which antibodies can be bound and which are easy to handle.

第一抗体としては、従来既知の方法で、ウサギ,ヤ
ギ,ヒツジ,モルモットなどの哺乳類動物に上記抗原性
物質を免疫することによって得られた複クローン抗体、
あるいは上記抗原性物質に対する抗体産生細胞(マウス
由来)とミエローマ細胞(マウス由来)を細胞融合して
得られたハイブリドーマ細胞を培養もしくは腹水化して
得られたマウス由来の単クローン抗体があげられる。こ
れら抗体は、硫安文画,DEAE−セルロースクロマトグラ
フィー,アフィニティークロマトグラフィー等の従来既
知の精製方法で精製して用いる。
The first antibody is a double-cloned antibody obtained by immunizing a mammal such as rabbit, goat, sheep, or guinea pig with the above antigenic substance by a conventionally known method.
Alternatively, there is a mouse-derived monoclonal antibody obtained by culturing or ascites the hybridoma cells obtained by cell fusion of antibody-producing cells (derived from mouse) against the above-mentioned antigenic substance and myeloma cells (derived from mouse). These antibodies are used after being purified by a conventionally known purification method such as ammonium sulfate, DEAE-cellulose chromatography, affinity chromatography and the like.

不溶性固体上に第一抗体を結合させる方法としては、
ガラスと抗体を化学的に結合させる(シランカップリン
グ剤および必要により架橋剤を用いて)方法(たとえば
特開昭54−108696号明細書)、または物理吸着させる方
法(たとえば米国特許第4280992号および第3652761号明
細書)、あるいはプラスチックに抗体を物理吸着させる
方法[たとえば、イー・エングバール,ジェー・ジョン
ソン,ピー・パールマン;バイオキム.バイオフィス.
アクタ(E.Engvall,J.Johnson,P.Parlmann;Biochim.Bio
phys.Acta),251(1971)427〜434]がある。
As a method of binding the first antibody on the insoluble solid,
A method of chemically bonding glass and an antibody (using a silane coupling agent and optionally a crosslinking agent) (for example, JP-A-54-108696) or a physical adsorption method (for example, US Pat. No. 4,280,992 and No. 3652761), or a method of physically adsorbing an antibody to a plastic [eg, E. Engbar, J. Johnson, P. Perlman; Biokim. Buy office.
Actor (E. Engvall, J. Johnson, P. Parlmann; Biochim. Bio
phys.Acta), 251 (1971) 427-434].

第二抗体としては、第一抗体と異なる動物種由来の上
記抗原性物質を認識する複クローン抗体(たとえば、第
一抗体がウサギの場合、ヤギ,ヒツジ,モルモットなど
の抗体;あるいは第一抗体がヒツジの場合、ウサギ,ヤ
ギ,モルモットなどの抗体);または第一抗体がマウス
以外の動物種由来の上記抗原性物質を認識する複クロー
ン抗体の場合、上記抗原性物質に対する抗体産生細胞
(マウス由来)とミエローマ細胞(マウス由来)を細胞
融合して得られたハイブリドーマ細胞を、培養もしくは
腹水化して得られた単クローン抗体があげられる。第二
抗体の形には、抗血清,ハイブリドーマ培養液,腹水,
もしくはこれらを精製して得られる免疫グロブリンなど
がある。
The second antibody is a monoclonal antibody that recognizes the above-mentioned antigenic substance derived from an animal species different from that of the first antibody (for example, when the first antibody is a rabbit, an antibody such as goat, sheep or guinea pig; or the first antibody is In the case of sheep, antibodies such as rabbits, goats, and guinea pigs); or, in the case where the first antibody is a monoclonal antibody that recognizes the above antigenic substance derived from an animal species other than mouse, antibody-producing cells (derived from mouse) against the above antigenic substance And a myeloma cell (derived from mouse), a monoclonal antibody obtained by culturing or ascites the hybridoma cell obtained by cell fusion. The form of the second antibody includes antiserum, hybridoma culture solution, ascites,
Alternatively, there are immunoglobulins obtained by purifying these.

第二抗体の免疫グロブリン濃度は、被検試料中の抗原
性物質の濃度およびペルオキシダーゼ標識抗体の濃度に
より種々の値をとりうるが、通常0.1〜1000μg/ml、好
ましくは1〜200μg/mlである。
The immunoglobulin concentration of the second antibody can take various values depending on the concentration of the antigenic substance and the concentration of the peroxidase-labeled antibody in the test sample, but is usually 0.1 to 1000 μg / ml, preferably 1 to 200 μg / ml. .

免疫複合体は、不溶性固体上の第一抗体と、抗原性物
質と、第二抗体とを、同時に反応させる方法によって得
ることができる。たとえば、第一抗体を結合させた不溶
性固体、抗原性物質を含む被検試料、および第二抗体含
有緩衝液を同時にインキュベーションすることにより、
免疫複合体を得ることができる。インキュベーション
は、通常の条件下(例えば5〜50℃,好ましくは30〜40
℃の温度、5分〜2日間,好ましくは5〜30分)で行う
ことができる。
The immune complex can be obtained by a method of simultaneously reacting the first antibody on the insoluble solid, the antigenic substance, and the second antibody. For example, by incubating an insoluble solid bound with a first antibody, a test sample containing an antigenic substance, and a second antibody-containing buffer at the same time,
An immune complex can be obtained. Incubation is carried out under normal conditions (eg 5 to 50 ° C, preferably 30 to 40 ° C).
The temperature may be 5 ° C to 2 days, preferably 5 to 30 minutes).

インキュベーションの後、洗浄液(たとえば蒸留水,
生理食塩水,リン酸緩衝液など)を加え、続けてアスピ
レーターで洗浄液を吸引除去する。この操作を数回(た
とえば2〜5回)行うことにより、免疫複合体を未反応
物と分離することができる。
After incubation, wash solution (eg distilled water,
Add physiological saline, phosphate buffer, etc.) and then aspirate the washing solution with an aspirator. By performing this operation several times (for example, 2 to 5 times), the immune complex can be separated from the unreacted substance.

第三抗体としては、第二抗体と同じ動物種由来の免疫
グロブリンを認識する抗体[たとえば、第二抗体がウサ
ギの場合、抗ウサギ免疫グロブリン抗体(モルモッ
ト);第二抗体がヤギ抗体の場合、抗ヤギ免疫グロブリ
ン抗体(マウス);あるいは第二抗体がマウスの場合、
抗マウス免疫グロブリン抗体(ウサギ)など]があげら
れる。
As the third antibody, an antibody that recognizes an immunoglobulin derived from the same animal species as the second antibody [for example, when the second antibody is a rabbit, an anti-rabbit immunoglobulin antibody (guinea pig); when the second antibody is a goat antibody, Anti-goat immunoglobulin antibody (mouse); or if the second antibody is mouse,
Anti-mouse immunoglobulin antibody (rabbit) and the like].

第一抗体、第二抗体、および第三抗体の組合わせとし
ては、非特異的吸着が少ないことから、第一抗体と第三
抗体は同じ動物種由来の抗体である。たとえば、第一抗
体ウサギ、第二抗体マウス単クローン、および第三抗体
ウサギ;第一抗体モルモット、第二抗体ヒツジ、および
第三抗体モルモット;第一抗体ヒツジ、第二抗体ウサ
ギ、および第三抗体ヒツジ;第一抗体ヤギ、第二抗体マ
ウス単クローン、および第三抗体ヤギなどがあげられ
る。特に好ましい組合わせは、抗原性物質に対して特異
性が高いことから、第一抗体ウサギ、第二抗体マウス単
クローン、および第三抗体ウサギ;あるいは第一抗体ヤ
ギ、第二抗体マウス単クローン、および第三抗体ヤギな
どである。
As a combination of the first antibody, the second antibody, and the third antibody, nonspecific adsorption is small, and thus the first antibody and the third antibody are derived from the same animal species. For example, a first antibody rabbit, a second antibody mouse monoclonal, and a third antibody rabbit; a first antibody guinea pig, a second antibody sheep, and a third antibody guinea pig; a first antibody sheep, a second antibody rabbit, and a third antibody. Sheep; first antibody goat, second antibody mouse monoclonal, and third antibody goat. Particularly preferred combination is, because of its high specificity for an antigenic substance, a first antibody rabbit, a second antibody mouse monoclonal clone, and a third antibody rabbit; or a first antibody goat, a second antibody mouse monoclonal clone, And the third antibody goat.

第三抗体に標識する酵素としてペルオキシダーゼを用
いるのは、アルカリフォスターゼやβ−ガラクトシダー
ゼを用いるのと比べ抗体標識が容易で、かつ高い感度が
得られることによる。
The reason why peroxidase is used as the enzyme for labeling the third antibody is that antibody labeling is easier and higher sensitivity can be obtained than when alkaline phosphatase or β-galactosidase is used.

ペルオキシダーゼによる第三抗体の標識は、通常の方
法で行うことができ、例えばエス・ヨシタケ,エム・イ
マガワ,イーイシカワ,エトール,ジェー・バイオケム
(S.YOSHITAKE,M.IMAGAWA,E.ISHIKAWA,et.al.,J.Bioche
m.,)92(1982)1413−1424記載の方法で行うことがで
きる。
Labeling of the third antibody with peroxidase can be performed by a conventional method, for example, S. YOSHITAKE, M. IMAGAWA, E.ISHIKAWA, et. al., J. Bioche
m.,) 92 (1982) 1413-1424.

本発明における、同時反応で得た免疫複合体とペルオ
キシダーゼ標識抗体との反応は通常の方法で行うことが
できる。例えば、ペルオキシダーゼ標識抗体溶液中に免
疫複合体を移し、インキュベーションすることにより行
なわれる。インキュベーションは、通常の条件下(例え
ば5〜50℃,好ましくは30〜40℃の温度、5分〜2日
間,好ましくは5〜30分)で行うことができる。
In the present invention, the reaction between the immune complex obtained by the simultaneous reaction and the peroxidase-labeled antibody can be performed by a usual method. For example, the immunocomplex is transferred to a peroxidase-labeled antibody solution and incubated. Incubation can be performed under usual conditions (for example, a temperature of 5 to 50 ° C, preferably 30 to 40 ° C, 5 minutes to 2 days, preferably 5 to 30 minutes).

上記免疫複合体とペルオキシダーゼ標識抗体との反応
生成物は、洗浄液(例えば蒸留水,生理食塩水,リン酸
緩衝液など)にて洗浄後、基質[たとえば5-アミノサリ
チル酸,o-フェニレンジアミン,ABTS〔2,2′‐アジノジ
(3-エチルベンズチアゾリン)‐6′‐スルホン酸〕な
ど、好ましくはo-フェニレンジアミン]溶液中に移し、
インキュベーションを行う。インキュベーションは、通
常の条件下(例えば5〜50℃,好ましくは30〜40℃の温
度、5分〜1時間,好ましくは5〜30分)で行うことが
できる。インキュベーションしたのち、反応停止液(た
とえば硫酸,塩酸など)を加え、吸光度によりペルオキ
シダーゼの酵素活性を定量する。
The reaction product of the above immunocomplex and the peroxidase-labeled antibody is washed with a washing solution (for example, distilled water, physiological saline, phosphate buffer, etc.), and then the substrate [for example, 5-aminosalicylic acid, o-phenylenediamine, ABTS [2,2'-azinodi (3-ethylbenzthiazoline) -6'-sulfonic acid], etc., preferably o-phenylenediamine]
Incubate. Incubation can be performed under normal conditions (for example, a temperature of 5 to 50 ° C., preferably 30 to 40 ° C., 5 minutes to 1 hour, preferably 5 to 30 minutes). After incubation, a reaction stop solution (for example, sulfuric acid, hydrochloric acid, etc.) is added, and the enzyme activity of peroxidase is quantified by the absorbance.

[実施例] 以下、実施例および比較例により、本発明をさらに説
明するが、本発明はこれに限定されるものではない。
[Examples] The present invention is further described below with reference to Examples and Comparative Examples, but the present invention is not limited thereto.

実施例1 [癌胎児性抗原(CEA)の測定] (a)ヒトCEA標準溶液の調製 大腸癌肝転移巣から過塩素酸抽出法により得られた高
値CEAをWHOのCEAインターナショナル リファレンス
スタンダード(63/701)を用いて、ダイナボット社製CE
A測定キット「CEA-EIA」により濃度を検定し、0.02Mリ
ン酸緩衝液で5,10,30および60ng/mlに調製した。
Example 1 [Measurement of Carcinoembryonic Antigen (CEA)] (a) Preparation of Human CEA Standard Solution High CEA obtained by perchloric acid extraction method from colorectal cancer liver metastases was used as WHO CEA International Reference.
CE manufactured by Dynabot, using the standard (63/701)
The concentration was assayed with the A measurement kit "CEA-EIA", and the concentration was adjusted to 5, 10, 30 and 60 ng / ml with 0.02M phosphate buffer.

(b)抗CEA単クローン抗体の製造 マウス(Balb/c)に高濃度のヒトCEAで免疫性を与え
た。6週間後、脾臓から細胞懸濁液を製造し、その後、
脾臓の約1×108個の細胞と約2×107個のマウスミエロ
ーマ(骨髄腫)細胞をPEG処理にて融合した。HAT培地中
で融合細胞を培養し、さらにスクリーニングにより、目
的とする抗体産生細胞(ハイブリドーマ)を選択した。
このハイブリドーマをクローニングにより単一細胞群
(単クローン)として増殖させ、次に単クローンをマウ
スにて腹水化した。得られた腹水を精製することによ
り、特異性の高い抗CEA単クローン免疫グロブリンを作
製した。
(B) Production of anti-CEA monoclonal antibody Mice (Balb / c) were immunized with a high concentration of human CEA. After 6 weeks, a cell suspension was prepared from the spleen and then
About 1 × 10 8 cells of spleen and about 2 × 10 7 mouse myeloma (myeloma) cells were fused by PEG treatment. The fused cells were cultured in HAT medium, and the target antibody-producing cells (hybridomas) were selected by screening.
This hybridoma was grown as a single cell group (single clone) by cloning, and then the single clone was subjected to ascites in mice. By purifying the obtained ascites, highly specific anti-CEA monoclonal immunoglobulin was prepared.

(c)ペルオキシダーゼ標識抗マウス免疫グロブリン抗
体の作製 抗マウス免疫グロブリン抗体(Dako社製)を前述の文
献[J.Biochem,92(1982)1413−1424]記載の方法にて
ペルオキシダーゼと結合し、ペルオキシダーゼ標識抗マ
ウス免疫グロブリン抗体を得た。この試薬は通常1%牛
血清アルブミン含有緩衝液で10〜5000倍に希釈して使用
した。
(C) Preparation of peroxidase-labeled anti-mouse immunoglobulin antibody An anti-mouse immunoglobulin antibody (manufactured by Dako) was bound to peroxidase by the method described in the above-mentioned document [J. Biochem, 92 (1982) 1413-1424] to give peroxidase. Labeled anti-mouse immunoglobulin antibody was obtained. This reagent was usually diluted with a buffer containing 1% bovine serum albumin 10 to 5000 times before use.

(d)抗CEA複クローン抗体結合ガラスビーズの作製 米国特許第3652761号明細書の方法に従い、ガラスビ
ーズの表面に抗CEA複クローン(ウサギ)抗体(Dako社
製)をコーティングした。
(D) Preparation of Anti-CEA Double Clone Antibody-Bound Glass Beads According to the method described in US Pat. No. 3652761, the surface of glass beads was coated with an anti-CEA double clone (rabbit) antibody (manufactured by Dako).

(e)ヒトCEAの定量 試験管内にて抗CEA複クローン(ウサギ)抗体結合ガ
ラスビーズ1コとヒトCEA標準溶液60ng/ml、50μlを抗
CEA単クローン抗体10〜100μg/ml含有0.02Mリン酸緩衝
液300μl中でインキュベーション(37℃,15分間)した
のち、蒸留水にてビーズを洗浄した。次に、ペルオキシ
ダーゼ標識抗マウス免疫グロブリン抗体溶液300μl中
にビーズを移し、インキュベーション(37℃,15分間)
した。再度、蒸留水にてビーズを洗浄したのち、ビーズ
を基質溶液(過酸化水素含有オルト−フェニレンジアミ
ン溶液)400μl中でインキュベーション(37℃,15分
間)した。次に、1.5規定硫酸3mlを加えて反応を停止し
た。この液の492nmの吸光度を測定し、ビーズに結合し
たペルオキシダーゼの酵素活性を定量した。
(E) Quantification of human CEA In vitro, anti-CEA double clone (rabbit) antibody-bonded glass beads (1) and human CEA standard solution (60 ng / ml, 50 μl)
After incubation in 300 μl of 0.02 M phosphate buffer containing 10 to 100 μg / ml of CEA monoclonal antibody (37 ° C., 15 minutes), the beads were washed with distilled water. Next, the beads were transferred to 300 μl of peroxidase-labeled anti-mouse immunoglobulin antibody solution and incubated (37 ° C, 15 minutes).
did. After washing the beads again with distilled water, the beads were incubated (37 ° C., 15 minutes) in 400 μl of the substrate solution (hydrogen peroxide-containing ortho-phenylenediamine solution). Next, the reaction was stopped by adding 3 ml of 1.5 N sulfuric acid. The absorbance of this solution at 492 nm was measured to quantify the enzyme activity of peroxidase bound to the beads.

同様に、ヒトCEA標準溶液30,10,5および0ng/mlを使用
した場合の酵素活性を測定し、検量線を作成した。
Similarly, the enzyme activity was measured when human CEA standard solutions 30, 10, 5 and 0 ng / ml were used to prepare a calibration curve.

第1図は本測定法によるヒトCEA測定の検量線であ
る。
FIG. 1 is a calibration curve for human CEA measurement by this measurement method.

また、測定感度、測定領域および測定精度は次のとお
りであった。
The measurement sensitivity, measurement area, and measurement accuracy were as follows.

測定感度 1.0ng/ml 測定領域 0〜60ng/ml 測定精度 5.0±0.4ng/ml(変動係数8.0%) 38.2±2.2ng/ml(変動係数5.8%) 比較例1 [従来のサンドイッチ法によるヒトCEAの測
定] 実施例1と比較するため、従来のサイドイッチ法によ
るヒトCEAの測定を行った。
Measurement sensitivity 1.0ng / ml Measurement area 0-60ng / ml Measurement accuracy 5.0 ± 0.4ng / ml (Coefficient of variation 8.0%) 38.2 ± 2.2ng / ml (Coefficient of variation 5.8%) Comparative Example 1 [Human CEA by conventional sandwich method Measurement] For comparison with Example 1, human CEA was measured by the conventional side-itch method.

(a)ヒトCEA標準溶液の調製 実施例1(a)に準じた。(A) Preparation of human CEA standard solution Same as in Example 1 (a).

(b)抗CEA単クローン免疫グロブリンの製造 実施例1(b)に準じた。(B) Production of Anti-CEA Monoclonal Immunoglobulin Same as in Example 1 (b).

(c)ペルオキシダーゼ標識抗CEA単クローン免疫グロ
ブリンの作製 実施例1(c)に準じて、上記抗CEA単クローン免疫
グロブリンをペルオキシダーゼと結合し、ペルオキシダ
ーゼ標識抗CEA単クローン免疫グロブリンを作製した。
この試薬は通常1%牛血清アルブミン含有緩衝液で10〜
5000倍に希釈して使用した。
(C) Preparation of Peroxidase-Labeled Anti-CEA Monoclonal Immunoglobulin According to Example 1 (c), the anti-CEA monoclonal immunoglobulin was bound to peroxidase to prepare a peroxidase-labeled anti-CEA monoclonal immunoglobulin.
This reagent is usually a 10% buffer containing 1% bovine serum albumin.
It was diluted 5000 times before use.

(d)抗CEA複クローン抗体結合ガラスビーズの作製 実施例1(d)に準じた。(D) Preparation of anti-CEA double-cloned antibody-bound glass beads Same as in Example 1 (d).

(e)CEAの定量 試験管内にて抗CEA複クローン(ウサギ)抗体結合ガラ
スビーズ1コとヒトCEA標準溶液60ng/ml、50μlを0.02
Mリン酸緩衝液200μl中でインキュベーション(37℃,1
5分間)したのち、蒸留水にてビーズを洗浄した。次
に、ペルオキシダーゼ標識抗CEA単クローン免疫グロブ
リン溶液300μlにビーズを移し、インキュベーション
(37℃,15分間)した。再度、蒸留水にてビーズを洗浄
したのち、ビーズを基質溶液(過酸化水素含有オルト−
フェニレンジアミン溶液)400μl中でインキュベーシ
ョン(37℃,15分間)した。次に、1.5規定硫酸3mlを加
えて反応を停止した。この液の492nmの吸光度を測定
し、ビーズに結合した酵素の酵素活性を定量した。同様
に、ヒトCEA標準溶液30,10,5および0ng/mlを使用した場
合の酵素活性を測定し、検量線を作成した。
(E) CEA quantification In a test tube, anti-CEA double clone (rabbit) antibody-bound glass beads (1) and human CEA standard solution 60 ng / ml, 50 μl 0.02
Incubation in 200 μl of M phosphate buffer (37 ℃, 1
After 5 minutes), the beads were washed with distilled water. Next, the beads were transferred to 300 μl of peroxidase-labeled anti-CEA monoclonal immunoglobulin solution and incubated (37 ° C., 15 minutes). After washing the beads again with distilled water, the beads were washed with a substrate solution (hydrogen peroxide-containing ortho-
Incubation (37 ° C., 15 minutes) in 400 μl of phenylenediamine solution). Next, the reaction was stopped by adding 3 ml of 1.5 N sulfuric acid. The absorbance of this solution at 492 nm was measured to quantify the enzyme activity of the enzyme bound to the beads. Similarly, the enzyme activity was measured when human CEA standard solutions 30, 10, 5 and 0 ng / ml were used to prepare a calibration curve.

第2図は比較例1によるヒトCEA測定の検量線であ
る。
FIG. 2 is a calibration curve for human CEA measurement according to Comparative Example 1.

また、測定感度、測定領域および測定精度は次のとお
りであった。
The measurement sensitivity, measurement area, and measurement accuracy were as follows.

測定感度 4.5ng/ml 測定領域 0〜60ng/ml 測定精度 5.3±0.9ng/ml(変動係数17.0%) 37.5±5.3ng/ml(変動係数14.1%) 比較例2 [三抗体遂次反応法によるヒトCEAの測定] 実施例1と比較するため、第一抗体と抗原性物質、抗
原性物質と第二抗体および第二抗体と第三抗体の反応を
遂次に行わせてヒトCEAの測定を行った。
Measurement sensitivity 4.5 ng / ml Measurement area 0-60 ng / ml Measurement accuracy 5.3 ± 0.9 ng / ml (variation coefficient 17.0%) 37.5 ± 5.3 ng / ml (variation coefficient 14.1%) Comparative Example 2 [Three antibody sequential reaction method Measurement of Human CEA] For comparison with Example 1, the reaction of the first antibody and the antigenic substance, the antigenic substance and the second antibody, and the reaction of the second antibody and the third antibody are successively performed to measure human CEA. went.

(a)ヒトCEA標準溶液の調製 実施例1(a)に準じた。(A) Preparation of human CEA standard solution Same as in Example 1 (a).

(b)抗CEA単クローン免疫グロブリンの製造 実施例1(b)に準じた。(B) Production of Anti-CEA Monoclonal Immunoglobulin Same as in Example 1 (b).

(c)ペルオキシダーゼ標識抗マウス免疫グロブリン抗
体の作製 実施例1(c)に準じた。
(C) Preparation of peroxidase-labeled anti-mouse immunoglobulin antibody This was carried out according to Example 1 (c).

(d)抗CEA複クローン抗体結合ガラスビーズの作製 実施例1(d)に準じた。(D) Preparation of anti-CEA double-cloned antibody-bound glass beads Same as in Example 1 (d).

(e)CEAの定量 試験管内にて抗CEA複クローン(ウサギ)抗体結合ガ
ラスビーズ1コとヒトCEA標準溶液60ng/ml50μlを0.02
Mリン酸緩衝液300μl中でインキュベーション(37℃,1
5分間)したのち、蒸留水にてビーズを洗浄した。次
に、抗CEA単クローン抗体10〜100μg/ml含有0.02Mリン
酸緩衝液300μl中にビーズを移し、インキュベーショ
ン(37℃,15分間)したのち、蒸留水にてビーズを洗浄
した。さらにペルオキシダーゼ標識抗マウス免疫グロブ
リン抗体溶液300μl中にビーズを移し、インキュベー
ション(37℃,15分間)した。再度、蒸留水にてビーズ
を洗浄したのち、ビーズを基質溶液(過酸化水素含有オ
ルト−フェニレンジアミン溶液)400μl中でインキュ
ベーション(37℃,15分間)した。次に、1.5規定硫酸3m
lを加えて反応を停止した。この液の492nmの吸光度を測
定し、ビーズに結合した酵素の酵素活性を定量した。
(E) CEA quantification In a test tube, anti-CEA double clone (rabbit) antibody-bound glass beads (1) and human CEA standard solution (60 ng / ml, 50 μl) were added 0.02
Incubation in 300 μl of M phosphate buffer (37 ℃, 1
After 5 minutes), the beads were washed with distilled water. Next, the beads were transferred to 300 μl of 0.02 M phosphate buffer containing 10 to 100 μg / ml of anti-CEA monoclonal antibody, incubated (37 ° C., 15 minutes), and then washed with distilled water. Further, the beads were transferred into 300 μl of peroxidase-labeled anti-mouse immunoglobulin antibody solution and incubated (37 ° C., 15 minutes). After washing the beads again with distilled water, the beads were incubated (37 ° C., 15 minutes) in 400 μl of the substrate solution (hydrogen peroxide-containing ortho-phenylenediamine solution). Next, 1.5 normal sulfuric acid 3m
The reaction was stopped by adding l. The absorbance of this solution at 492 nm was measured to quantify the enzyme activity of the enzyme bound to the beads.

同様に、ヒトCEA標準溶液30,10,5および0ng/mlを使用
した場合の酵素活性を測定し、検量線を作成した。
Similarly, the enzyme activity was measured when human CEA standard solutions 30, 10, 5 and 0 ng / ml were used to prepare a calibration curve.

第3図は比較例2によるヒトCEA測定の検量線であ
る。
FIG. 3 is a calibration curve for human CEA measurement according to Comparative Example 2.

また、測定感度、測定領域および測定精度は次のとお
りであった。
The measurement sensitivity, measurement area, and measurement accuracy were as follows.

測定感度 3.9ng/ml 測定領域 0〜60ng/ml 測定精度 6.6±0.9ng/ml (変動係数 13.6%) 40.2±5.8ng/ml (変動係数 14.4%) 実施例2 [甲状腺刺激ホルモン(TSH)の測定] (a)ヒトTSH標準溶液の調製 UCBバイオプロダクツ社より入手したヒトTSH(50μg/
バイアル)を0.02Mリン酸緩衝液にて希釈し、50,25,5,
2.5および0 IU/mlのヒトTSH標準溶液を調製した。
Measurement sensitivity 3.9 ng / ml Measurement area 0-60 ng / ml Measurement accuracy 6.6 ± 0.9 ng / ml (variation coefficient 13.6%) 40.2 ± 5.8 ng / ml (variation coefficient 14.4%) Example 2 [of thyroid stimulating hormone (TSH)] Measurement] (a) Preparation of human TSH standard solution Human TSH obtained from UCB Bioproducts (50 μg /
Vial) diluted with 0.02M phosphate buffer, 50, 25, 5,
2.5 and 0 IU / ml human TSH standard solutions were prepared.

(b)抗TSH単クローン抗体の製造 上記ヒトTSHを使用し、実施例1(b)の方法に従
い、抗ヒトTSH単クローン抗体を得た。
(B) Production of anti-TSH monoclonal antibody Using the above human TSH, an anti-human TSH monoclonal antibody was obtained according to the method of Example 1 (b).

(c)抗TSH複クローン抗体結合ガラスビーズの作製 抗TSH複クローン(ウサギ)抗体(Dako社製)を使用
し、実施例1(d)の方法により、抗TSH複クローン抗
体結合ガラスビーズを得た。
(C) Preparation of anti-TSH double-cloned antibody-bound glass beads Anti-TSH double-cloned (rabbit) antibody (manufactured by Dako) was used to obtain anti-TSH double-cloned antibody-bound glass beads by the method of Example 1 (d). It was

(d)ヒトTSHの定量 試験管内にて、抗TSH複クローン(ウサギ)抗体結合
ガラスビーズ1コとヒトTSH標準50IU/ml溶液100μlを
抗TSH単クローン抗体10〜100μg/ml含有0.02Mリン酸緩
衝液200μl中でインキュベーション(37℃,30〜60分
間)したのち、蒸留水にてビーズを洗浄した。実施例1
(c)で作製したペルオキシダーゼ標識抗マウス免疫グ
ロブリン抗体溶液300μl中にビーズを移し、インキュ
ベーション(37℃,30〜60分間)した。再度、蒸留水に
てビーズを洗浄したのち、ビーズを基質溶液(過酸化水
素含有オルト−フェニレンジアミン溶液)400μl中で
インキュベーション(10〜30℃,30分間)した。次に、
1.5規定硫酸3mlを加えて反応を停止した。この液の492n
mの吸光度を測定し、ビーズに結合した酵素の酵素活性
を定量した。
(D) Quantification of human TSH In a test tube, 1 glass of anti-TSH double-cloned (rabbit) antibody-bound glass and 100 μl of human TSH standard 50 IU / ml solution were added to anti-TSH monoclonal antibody in an amount of 10 to 100 μg / ml and 0.02 M phosphoric acid After incubation in 200 μl of buffer (37 ° C., 30 to 60 minutes), the beads were washed with distilled water. Example 1
The beads were transferred to 300 μl of the peroxidase-labeled anti-mouse immunoglobulin antibody solution prepared in (c) and incubated (37 ° C., 30 to 60 minutes). After washing the beads again with distilled water, the beads were incubated (10 to 30 ° C., 30 minutes) in 400 μl of a substrate solution (ortho-phenylenediamine solution containing hydrogen peroxide). next,
The reaction was stopped by adding 3 ml of 1.5N sulfuric acid. 492n of this liquid
The absorbance of m was measured to quantify the enzyme activity of the enzyme bound to the beads.

同様に、ヒトTSH標準溶液25,5,2.5および0IU/mlを被
検試料とした場合の酵素活性を測定し、検量線を作成し
た。
Similarly, the enzyme activity was measured when human TSH standard solutions 25, 5, 2.5 and 0 IU / ml were used as test samples, and a calibration curve was prepared.

第4図は、実施例2によるヒトTSH測定の検量線であ
る。
FIG. 4 is a calibration curve for human TSH measurement according to Example 2.

また、測定感度、測定領域、および測定精度は次のと
おりであった。
The measurement sensitivity, measurement area, and measurement accuracy were as follows.

測定感度 2.0IU/ml 測定領域 0〜50IU/ml 測定精度 2.8±0.2IU/ml(変動係数 7.1%) 26.0±1.4ng/ml(変動係数 5.4%) 比較例3 [従来のサンドイッチ法によるヒトTSHの測
定] 実施例2と比較するため、従来のサンドイッチ法によ
るヒトTSHの測定を行った。
Measurement sensitivity 2.0 IU / ml Measurement area 0-50 IU / ml Measurement accuracy 2.8 ± 0.2 IU / ml (variation coefficient 7.1%) 26.0 ± 1.4 ng / ml (variation coefficient 5.4%) Comparative Example 3 [Human TSH by conventional sandwich method Measurement] For comparison with Example 2, human TSH was measured by the conventional sandwich method.

(a)ヒトTSH標準溶液の調製 実施例2(a)に準じた。(A) Preparation of human TSH standard solution Same as in Example 2 (a).

b)抗TSH単クローン免疫グロブリンの製造 実施例2(b)に準じた。b) Production of Anti-TSH Monoclonal Immunoglobulin Same as in Example 2 (b).

(c)ペルオキシダーゼ標識抗TSH単クローン免疫グロ
ブリンの作製 実施例1(c)に準じて、上記抗TSH単クローン免疫
グロブリンをペルオキシダーゼと結合し、ペルオキシダ
ーゼ標識抗TSH単クローン免疫グロブリンを作製した。
この試薬は、通常1%牛血清アルブミン含有緩衝液で10
〜5000倍に希釈して使用した。
(C) Preparation of Peroxidase-Labeled Anti-TSH Monoclonal Immunoglobulin According to Example 1 (c), the above anti-TSH monoclonal immunoglobulin was combined with peroxidase to prepare a peroxidase-labeled anti-TSH monoclonal immunoglobulin.
This reagent is usually 10% buffer containing 1% bovine serum albumin.
It was used after diluting ~ 5000 times.

(d)抗TSH複クローン抗体結合ガラスビーズの作製 実施例2(c)に準じた。(D) Preparation of anti-TSH double-cloned antibody-bound glass beads Same as in Example 2 (c).

(e)TSHの定量 試験管内にて抗TSH複クローン抗体結合ガラスビーズ
1コとヒトTSH標準50IU/ml溶液100μlを抗TSH複クロー
ン抗体10〜100μg/ml含有0.02Mリン酸緩衝液200μl中
でインキュベーション(37℃,60分間)したのち、蒸留
水にてビーズを洗浄した。次にペルオキシダーゼ標識抗
TSH単クローン免疫グロブリン溶液300μl中にビーズを
移し、インキュベーション(37℃,60分間)した。再
度、蒸留水にてビーズを洗浄したのち、ビーズを基質溶
液(過酸化水素含有オルト−フェニレンジアミン溶液)
400μl中でインキュベーション(37℃,30分間)した。
次に、1.5規定硫酸3mlを加えて反応を停止した。この液
の492nmの吸光度を測定し、ビーズに結合した酵素の酵
素活性を定量した。
(E) Quantification of TSH In a test tube, 1 glass of anti-TSH double-cloned antibody-bonded glass beads and 100 μl of human TSH standard 50 IU / ml solution in 200 μl of 0.02 M phosphate buffer containing 10-100 μg / ml of anti-TSH double-cloned antibody. After incubation (37 ° C., 60 minutes), the beads were washed with distilled water. Then peroxidase-labeled
The beads were transferred into 300 μl of TSH monoclonal immunoglobulin solution and incubated (37 ° C., 60 minutes). After washing the beads again with distilled water, the beads are used as a substrate solution (hydrogen peroxide-containing ortho-phenylenediamine solution).
Incubation (37 ° C., 30 minutes) in 400 μl.
Next, the reaction was stopped by adding 3 ml of 1.5 N sulfuric acid. The absorbance of this solution at 492 nm was measured to quantify the enzyme activity of the enzyme bound to the beads.

同様に、ヒトTSH標準溶液25,5,2.5および0IU/mlを用
いた場合の酵素活性を測定し、検量線を作成した。
Similarly, the enzyme activity was measured using human TSH standard solutions 25, 5, 2.5 and 0 IU / ml, and a calibration curve was prepared.

第5図は、比較例3によるヒトTSH測定の検量線であ
る。
FIG. 5 is a calibration curve for human TSH measurement according to Comparative Example 3.

また、測定感度、測定領域および測定精度は次のとお
りであった。
The measurement sensitivity, measurement area, and measurement accuracy were as follows.

測定感度 6.5IU/ml 測定領域 0〜50IU/ml 測定精度 2.6±0.7IU/ml(変動係数 26.9%) 25.5±4.3IU/ml(変動係数 16.9%) 比較例4 [三抗体遂次反応法によるヒトTSHの測定] 実施例2と比較するため、従来の三抗体サンドイッチ
遂次反応法によるヒトTSHの測定を行った。
Measurement sensitivity 6.5 IU / ml Measurement area 0-50 IU / ml Measurement accuracy 2.6 ± 0.7 IU / ml (Variation coefficient 26.9%) 25.5 ± 4.3 IU / ml (Variation coefficient 16.9%) Comparative example 4 [Three antibody sequential reaction method Measurement of Human TSH] For comparison with Example 2, human TSH was measured by the conventional three antibody sandwich sequential reaction method.

(a)ヒトTSH標準溶液の調製 実施例2(a)に準じた。(A) Preparation of human TSH standard solution Same as in Example 2 (a).

(b)抗TSH単クローン抗体の製造 実施例2(b)に準じた。(B) Production of anti-TSH monoclonal antibody This was carried out according to Example 2 (b).

(c)抗TSH複クローン抗体結合ガラスビーズの作製 実施例2(c)に準じた。(C) Preparation of anti-TSH double-cloned antibody-bound glass beads Same as in Example 2 (c).

(d)ヒトTSHの定量 試験管内にて、抗TSH複クローン(ウサギ)抗体結合
ガラスビーズ1コとヒトTSH標準50IU/ml溶液100μlを
0.02Mリン酸緩衝液200μl中でインキュベーション(37
℃,30分間)したのち、蒸留水にてビーズを洗浄した。
次に抗TSH単クローン抗体10〜100μg/ml含有0.02Mリン
酸緩衝液300μl中にビーズを移し、インキュベーショ
ン(37℃,30分間)したのち、蒸留水にてビーズを洗浄
した。さらに実施例1(c)で作製したペルオキシダー
ゼ標識抗マウス免疫グロブリン抗体溶液300μl中にビ
ーズを移し、インキュベーション(37℃,30分間)し
た。再度、蒸留水にてビーズを洗浄したのち、ビーズを
基質溶液(過酸化水素含有オルト−フェニレンジアミン
溶液)400μl中でインキュベーション(37℃,30分間)
した。次に、1.5規定硫酸3mlを加えて反応を停止した。
この液の492nmの吸光度を測定し、ビーズに結合した酵
素の酵素活性を定量した。
(D) Quantification of human TSH 1 tube of anti-TSH double clone (rabbit) antibody-bound glass beads and 100 μl of human TSH standard 50 IU / ml solution were placed in a test tube.
Incubation in 200 μl of 0.02 M phosphate buffer (37
Then, the beads were washed with distilled water.
Next, the beads were transferred to 300 μl of 0.02 M phosphate buffer containing 10-100 μg / ml of anti-TSH monoclonal antibody, incubated (37 ° C., 30 minutes), and then washed with distilled water. Furthermore, the beads were transferred to 300 μl of the peroxidase-labeled anti-mouse immunoglobulin antibody solution prepared in Example 1 (c) and incubated (37 ° C., 30 minutes). After washing the beads again with distilled water, the beads were incubated in 400 μl of the substrate solution (hydrogen peroxide-containing ortho-phenylenediamine solution) (37 ° C, 30 minutes).
did. Next, the reaction was stopped by adding 3 ml of 1.5 N sulfuric acid.
The absorbance of this solution at 492 nm was measured to quantify the enzyme activity of the enzyme bound to the beads.

同様に、ヒトTSH標準溶液25,5,2.5および0IU/mlを被
検試料とした場合の酵素活性を測定し、検量線を作成し
た。
Similarly, the enzyme activity was measured when human TSH standard solutions 25, 5, 2.5 and 0 IU / ml were used as test samples, and a calibration curve was prepared.

第6図は比較例4によるヒトTSH測定の検量線であ
る。
FIG. 6 is a calibration curve for human TSH measurement according to Comparative Example 4.

また、測定感度、測定領域および測定精度は次のとお
りであった。
The measurement sensitivity, measurement area, and measurement accuracy were as follows.

測定感度 5.7IU/ml 測定領域 0〜50IU/ml 測定精度 3.0±0.6IU/ml (変動係数 20.0%) 28.2±4.7IU/ml (変動係数 16.6%) [発明の効果] 従来のサイドイッチ法では、酵素標識する第二抗体の
抗体価が低い場合、測定感度・精度とも低くなり、通常
の測定が不可能であった。そこで、三抗体遂次法による
測定を試みたが、若干の感度アップは認められるもの
の、有効な測定法とはなり得なかった。
Measurement sensitivity 5.7 IU / ml Measurement area 0-50 IU / ml Measurement accuracy 3.0 ± 0.6 IU / ml (Variation coefficient 20.0%) 28.2 ± 4.7 IU / ml (Variation coefficient 16.6%) [Effect of the invention] In the conventional side-itch method When the antibody titer of the enzyme-labeled secondary antibody was low, both the measurement sensitivity and accuracy were low, and normal measurement was impossible. Therefore, an attempt was made to measure by the three-antibody sequential method, but although the sensitivity was slightly increased, it could not be an effective measuring method.

本発明の測定法によれば、第二抗体の抗体価が低い場
合でも十分な測定感度が得られる。たとえば、第二抗体
が抗血清、培養液もしくは腹水などの未精製抗体の場合
でも高感度が得られる。また、第二抗体に単クローン抗
体を用いた場合は、目的とする抗原性物質に対して特異
性の高い測定が可能となる。
According to the assay method of the present invention, sufficient assay sensitivity can be obtained even when the antibody titer of the secondary antibody is low. For example, high sensitivity can be obtained even when the second antibody is an unpurified antibody such as antiserum, culture solution or ascites fluid. Further, when a monoclonal antibody is used as the second antibody, it is possible to perform highly specific measurement with respect to the target antigenic substance.

以上の点から、本発明は特に高感度の測定系が要求さ
れる抗原性物質であるCEAおよびTSHの診断試薬に応用で
きる。
From the above points, the present invention can be applied to diagnostic reagents for CEA and TSH, which are antigenic substances for which particularly sensitive measurement systems are required.

【図面の簡単な説明】[Brief description of drawings]

第1図、第2図および第3図はヒトCEA測定の検量線、
第4図、第5図および第6図はヒトTSHの検量線であ
る。
Figures 1, 2 and 3 show the calibration curve for human CEA measurement,
FIG. 4, FIG. 5 and FIG. 6 are calibration curves of human TSH.

───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 昭60−187861(JP,A) 特開 昭59−163565(JP,A) 特開 昭61−40568(JP,A) ─────────────────────────────────────────────────── ─── Continuation of the front page (56) References JP 60-187861 (JP, A) JP 59-163565 (JP, A) JP 61-40568 (JP, A)

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】癌胎児性抗原(CEA)および甲状腺刺激ホ
ルモン(TSH)から選ばれる抗原性物質を認識する不溶
性固体上の抗体(第一抗体)、前記CEAおよびTSHから選
ばれる抗原性物質、および前記第一抗体とは異なる動物
種由来の前記抗原性物質を認識する抗体(第二抗体)を
同時に反応させて得た免疫複合体と、 ペルオキシダーゼで標識された、前記第一抗体と同じ動
物種由来の抗体であり、第二抗体と同じ動物種由来の免
疫グロブリンを認識するペルオキシダーゼ標識抗体(第
三抗体) とを反応させたのち、ペルオキシダーゼ量を測定するこ
とにより、前記抗原性物質を定量することを特徴とする
酵素免疫測定法。
1. An antibody (first antibody) on an insoluble solid that recognizes an antigenic substance selected from carcinoembryonic antigen (CEA) and thyroid stimulating hormone (TSH), the antigenic substance selected from CEA and TSH, And an immune complex obtained by simultaneously reacting an antibody (second antibody) that recognizes the antigenic substance derived from an animal species different from the first antibody, and the same animal as the first antibody labeled with peroxidase The antigenic substance is quantified by reacting with a peroxidase-labeled antibody (a third antibody) that is a species-derived antibody that recognizes immunoglobulin derived from the same animal species as the second antibody, and then measures the amount of peroxidase. An enzyme immunoassay method characterized by:
【請求項2】第二抗体が単クローン抗体である特許請求
の範囲第1項記載の測定法。
2. The assay method according to claim 1, wherein the second antibody is a monoclonal antibody.
【請求項3】不溶性固体がガラスまたはプラスチックで
ある特許請求の範囲第1項または第2項に記載の測定
法。
3. The measuring method according to claim 1 or 2, wherein the insoluble solid is glass or plastic.
JP62083656A 1986-05-13 1987-04-03 Enzyme immunoassay Expired - Fee Related JPH081438B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61-109831 1986-05-13
JP10983186 1986-05-13

Publications (2)

Publication Number Publication Date
JPS63118656A JPS63118656A (en) 1988-05-23
JPH081438B2 true JPH081438B2 (en) 1996-01-10

Family

ID=14520310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62083656A Expired - Fee Related JPH081438B2 (en) 1986-05-13 1987-04-03 Enzyme immunoassay

Country Status (4)

Country Link
JP (1) JPH081438B2 (en)
DE (1) DE3715984A1 (en)
FR (1) FR2598811A1 (en)
GB (1) GB2190490B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108907T1 (en) * 1987-11-28 1994-08-15 Cambridge Patent Dev DETERMINATION METHOD, ITS USE AND COMPONENTS.
US5468651A (en) * 1987-11-28 1995-11-21 Cambridge Patent Developments Limited Method for determining haptens, use of method and components useful in method
EP0597951B1 (en) * 1991-07-26 1999-03-31 Dade Chemistry Systems Inc. An assay with signal detection in the presence of a suspended solid support
US5366859A (en) * 1991-10-31 1994-11-22 Mitsubishi Petrochemical Co., Ltd. Radioimmunoassay method
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
US6201109B1 (en) 1993-01-13 2001-03-13 Dade Behring Marburg Gmbh Assay for bone alkaline phosphatase
DE19859912C2 (en) * 1998-12-23 2001-06-21 Aventis Res & Tech Gmbh & Co Test system for the detection of different markers, its production and use
USRE46351E1 (en) 2001-05-10 2017-03-28 Battelle Energy Alliance, Llc Antibody profiling sensitivity through increased reporter antibody layering
US20080286881A1 (en) * 2007-05-14 2008-11-20 Apel William A Compositions and methods for combining report antibodies
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
US8969009B2 (en) 2009-09-17 2015-03-03 Vicki S. Thompson Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
US9410965B2 (en) 2009-09-17 2016-08-09 Battelle Energy Alliance, Llc Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7501215A (en) * 1975-02-01 1976-08-03 Akzo Nv METHOD FOR DETERMINING AND DETERMINING AN ANTIGEN OR ANTIBODY.
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
DE3225027A1 (en) * 1982-07-05 1984-01-05 Boehringer Mannheim Gmbh, 6800 Mannheim IMMUNCHEMICAL MEASUREMENT METHOD
JPS59163565A (en) * 1983-03-08 1984-09-14 Toray Ind Inc Microdetermination method of high molecular antigen
EP0125893A3 (en) * 1983-05-12 1986-10-15 Sumitomo Chemical Company, Limited The quantitative analysis of antigen by the enzyme-antibody bridge method
JPS60187861A (en) * 1984-03-07 1985-09-25 Sumitomo Chem Co Ltd Assay of interferon by enzyme antibody cross linking method
JPS6140568A (en) * 1984-07-31 1986-02-26 Kyowa Hakko Kogyo Co Ltd Enzyme-immunoassay
US4748110A (en) * 1985-09-25 1988-05-31 Abbott Laboratories Immunoassay for HTLV-III antigens

Also Published As

Publication number Publication date
GB2190490A (en) 1987-11-18
JPS63118656A (en) 1988-05-23
GB2190490B (en) 1990-02-28
DE3715984A1 (en) 1987-11-19
FR2598811A1 (en) 1987-11-20
GB8711055D0 (en) 1987-06-17

Similar Documents

Publication Publication Date Title
US5262296A (en) Freeze-dried composition containing enzyme-labeled anti-human interferon-β antibody and enzyme immunoassay kit containing the composition
US4434227A (en) Immunoassay for class specific immunoglobulin antibodies
IE890683L (en) Method for determination of a polyvalent substance using an immunoaggregate
GB2074727A (en) Immunological diagnostic method
JPH0239747B2 (en)
JPS61144573A (en) Sandwich immunoassay
JPS62284262A (en) Immonoassay method
WO2022193980A1 (en) Antibody or antigen-binding fragment thereof for novel coronavirus nucleocapsid protein, and application thereof
US4670383A (en) Immune-chemical measurement process for haptens and proteins
JPH081438B2 (en) Enzyme immunoassay
US5366859A (en) Radioimmunoassay method
CA1338324C (en) Monoclonal antibody for the selective immunological determination of intact procollagen peptide (type iii) and procollagen (type iii) in body fluids
JP2867325B2 (en) Anti-PIVKA-II antibody producing hybridoma and immunological assay method
JP2736058B2 (en) Manufacturing method of immunoassay device
Hill et al. A sensitive enzyme-linked immunosorbent assay for the quantitation of antigen-specific murine immunoglobulin E1
Vonk et al. Dual-enzyme cascade-magnetic separation immunoassay for respiratory syncytial virus
CA2281262C (en) Anti-human medullasin monoclonal antibody, process for producing the same and immunoassay using the same
CA2057693A1 (en) Method for the determination of antibodies against lipocortins
EP0368674A2 (en) Immunoassay and test kits therefor
JPH0754323B2 (en) Immunoassays and immunoassay reagents
JPH0518974A (en) Immunological measuring method
JP3299787B2 (en) Radioimmunoassay
JP2816767B2 (en) Method for producing immobilized antibody
Savelkoul et al. Quantitation of murine IgE in an automatic ELISA system
JPH04221762A (en) Immunological measuring method

Legal Events

Date Code Title Description
LAPS Cancellation because of no payment of annual fees